SFDA Revises China GMP Guidelines, Seeks Comments On Local Impact
This article was originally published in The Gold Sheet
China's GMP update could be tough for China's domestic drug, API manufacturers.
You may also be interested in...
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
SHANGHAI – China’s State FDA released its long-awaited good manufacturing practice guidelines for pharmaceutical products Feb. 12.